Adalvo’s DCP for Tacrolimus 0.03% and 0.1% Ointment is making significant progress, with closure planned for Q3 2025.
Engineered for effective dermal delivery, Tacrolimus Ointment represents a highly specialized R&D achievement, particularly due to the stringent requirements of in vitro equivalence testing.
Manufactured through a fully European supply chain, the product reflects Adalvo’s continued commitment to quality, access, and market differentiation.
Backed by global MAT sales of $363 million in 2024 and a 3-year CAGR of 11% (IQVIA), Tacrolimus Ointment offers strong potential in a category where topical immunomodulators play a vital role in patient care.
Click here to Request Access to Adalvo’s Dermatology Portfolio
Adalvo’s strategic vision ensures we remain ahead of the curve, providing partners with access to competitive, first-to-market products in high-demand therapeutic areas.
Partner up now!